Abstract
The major phenomenon that we are all dealing in the kidney cancer space is the power of the immuno-oncology agents to effect complete responses. For the first- line therapy, physicians have f our FDA approved regimens to choose from: nivolumab/ipilimumab, pembrolizumab/axitinib, nivolumab/cabometyx, pembro/lenvantinib, and of course clinical trials. Nivolumab/ipilimumab combination has big advantages and performs dramatically well in eliminating the tumors in certain RCC patients. In some patients, complete response is attained fairly quickly within three months. Such complete responses are well documented both clinically and sometimes surgically by nephrectomy. Such highly impressive outcomes are driving a lot of physicians who are on the fence between nivolumab/ipilimumab versus pembrolizumab/axitinib to go with nivolumab and ipilimumab.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
